A public report, opened upNovartis 2025.
Novartis 2025.
Follow the numbers.
What sold, what became profit, where the cash went. Explore the same financial report from several angles, then go back to the page behind any figure.
54 pages reviewedQ4 & full year 2025
Condensed Financial Report
Supplementary Data
Full year 2025 vs Full year 2024 · USD millions unless statedSaved calculation
Start with the income statement
Trace the full-year change in operating income.
The movements below reconcile the change between two reported periods. They show which financial lines changed; they do not establish the operational cause.
Year-on-year reported operating-income movement
Residual 0 USD millionSeven non-overlapping signed P&L changes; gross-profit subtotal is excluded. Arithmetic contributions do not establish operational causes.
p. 18Exact movements and calculation
current − prior = sum of signed contributions
| Line item | From / prior | To / current | Change | Unit / basis | Source |
|---|---|---|---|---|---|
| Net sales | 50,317 | 54,532 | +4,215 | USD millionIFRS reported | p. 18 |
| Other revenues | 1,405 | 2,142 | +737 | USD millionIFRS reported | p. 18 |
| Cost of goods sold | -12,827 | -13,699 | −872 | USD millionIFRS reported | p. 18 |
| Selling, general and administration | -12,566 | -13,248 | −682 | USD millionIFRS reported | p. 18 |
| Research and development | -10,022 | -11,200 | −1,178 | USD millionIFRS reported | p. 18 |
| Other income | 1,175 | 1,460 | +285 | USD millionIFRS reported | p. 18 |
| Other expense | -2,938 | -2,343 | +595 | USD millionIFRS reported | p. 18 |
R&D expense / net sales20.54 %
Prior: 19.92 %
What makes up other revenues?
| Line item | Full year 2024 | Full year 2025 | Change | Unit / basis | Source |
|---|---|---|---|---|---|
| Profit sharing income | 1,063 | 1,341 | +278 | USD millionIFRS reported | p. 41 |
| Royalty income | 37 | 379 | +342 | USD millionIFRS reported | p. 41 |
| Milestone income | 28 | 117 | +89 | USD millionIFRS reported | p. 41 |
| Other revenue | 277 | 305 | +28 | USD millionIFRS reported | p. 41 |
| Total other revenues | 1,405 | 2,142 | +737 | USD millionIFRS reported | p. 41 |
Full income statement, including EPS and share counts
| Line item | Full year 2024 | Full year 2025 | Change | Unit / basis | Source |
|---|---|---|---|---|---|
| Net sales | 50,317 | 54,532 | +4,215 | USD millionIFRS reported | p. 18 |
| Other revenues | 1,405 | 2,142 | +737 | USD millionIFRS reported | p. 18 |
| Cost of goods sold | -12,827 | -13,699 | −872 | USD millionIFRS reported | p. 18 |
| Gross profit | 38,895 | 42,975 | +4,080 | USD millionIFRS reported | p. 18 |
| Selling, general and administration | -12,566 | -13,248 | −682 | USD millionIFRS reported | p. 18 |
| Research and development | -10,022 | -11,200 | −1,178 | USD millionIFRS reported | p. 18 |
| Other income | 1,175 | 1,460 | +285 | USD millionIFRS reported | p. 18 |
| Other expense | -2,938 | -2,343 | +595 | USD millionIFRS reported | p. 18 |
| Operating income | 14,544 | 17,644 | +3,100 | USD millionIFRS reported | p. 18 |
| Loss from associated companies | -38 | -12 | +26 | USD millionIFRS reported | p. 18 |
| Interest expense | -1,006 | -1,144 | −138 | USD millionIFRS reported | p. 18 |
| Other financial income and expense | 140 | -136 | −276 | USD millionIFRS reported | p. 18 |
| Income before taxes | 13,640 | 16,352 | +2,712 | USD millionIFRS reported | p. 18 |
| Income taxes | -1,701 | -2,385 | −684 | USD millionIFRS reported | p. 18 |
| Net income | 11,939 | 13,967 | +2,028 | USD millionIFRS reported | p. 18 |
| Net income attributable to Novartis AG shareholders | 11,941 | 13,984 | +2,043 | USD millionIFRS reported | p. 18 |
| Net income attributable to non-controlling interests | -2 | -17 | −15 | USD millionIFRS reported | p. 18 |
| Weighted average basic shares | 2,018 | 1,939 | −79 | million sharesIFRS reported | p. 18 |
| Basic earnings per share | 5.92 | 7.21 | +1.29 | USD per shareIFRS reported | p. 18 |
| Weighted average diluted shares | 2,035 | 1,955 | −80 | million sharesIFRS reported | p. 18 |
| Diluted earnings per share | 5.87 | 7.15 | +1.28 | USD per shareIFRS reported | p. 18 |
Reviewed data. Reproducible calculations.
Showing the saved calculation. Refresh to ask the Python service to calculate it again.